Novartis AG Gross Profit Growth & History (NVS)
Novartis AG's gross profit was $42.98B for fiscal 2025.
View full Novartis AG company overviewNovartis AG annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $42.98B | $4.08B | +10.49% |
| 2024 | 2024-12-31 | $38.90B | $4.71B | +13.77% |
| 2023 | 2023-12-31 | $34.19B | $2.31B | +7.24% |
| 2022 | 2022-12-31 | $31.88B | −$360.0M | −1.12% |
| 2021 | 2021-12-31 | $32.24B | −$2.54B | −7.30% |
| 2020 | 2020-12-31 | $34.78B | $525.0M | +1.53% |
| 2019 | 2019-12-31 | $34.25B | $2.66B | +8.43% |
| 2018 | 2018-12-31 | $31.59B | $1.82B | +6.11% |
| 2017 | 2017-12-31 | $29.77B | −$2.15B | −6.72% |
| 2016 | 2016-12-31 | $31.92B | — | — |
Novartis AG quarterly gross profit
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $11.24B | −$273.0M | −2.37% |
| Q1 2026 | 2026-03-31 | $10.06B | — | — |
| Q4 2025 | 2025-12-31 | $10.25B | — | — |
| Q3 2025 | 2025-09-30 | $10.82B | — | — |
| Q2 2025 | 2025-06-30 | $11.51B | $1.81B | +18.71% |
| Q2 2024 | 2024-06-30 | $9.70B | $1.30B | +15.42% |
| Q2 2023 | 2023-06-30 | $8.40B | −$931.0M | −9.97% |
| Q2 2022 | 2022-06-30 | $9.33B | −$46.0M | −0.49% |
| Q2 2021 | 2021-06-30 | $9.38B | $1.19B | +14.49% |
| Q2 2020 | 2020-06-30 | $8.19B | −$425.0M | −4.93% |
| Q2 2019 | 2019-06-30 | $8.62B | $523.0M | +6.46% |
| Q2 2018 | 2018-06-30 | $8.10B | −$141.0M | −1.71% |
| Q2 2017 | 2017-06-30 | $8.24B | — | — |
Novartis AG gross profit trends
Over the last five fiscal years, Novartis AG's gross profit increased from $34.78B to $42.98B, a change of $8.20B. The latest reported quarter, Q2 2026, shows $11.24B.
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novartis AG source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...